

Supplementary material has been published as submitted. It has not been copyedited or typeset by Acta Oncologica.

<b>Table S1. Combinations of ER and PR status by the three methods in 313 patients</b>				
	<b>Cytosol</b>	<b>IHC</b>	<b>GEX*</b>	<b>Number of patients</b>
<b>ER</b>	+	+	+	178
	+	+	-	0
	+	-	+	6
	+	-	-	4
	-	+	+	33
	-	+	-	2
	-	-	+	6
	-	-	-	84
				<i>Total</i> 313
				51 (16) Discordant evaluation No. (%)
<b>PR</b>	+	+	+	177
	+	+	-	2
	+	-	+	12
	+	-	-	11
	-	+	+	13
	-	+	-	1
	-	-	+	7
	-	-	-	90
				<i>Total</i> 313
				46 (15) Discordant evaluation No. (%)

Patients with available data for all methods for ER and PR included (n=313).  
*Cytosol*, cytosol-based method; *IHC*, immunohistochemistry; *GEX*, gene expression.  
 \*Positive gene expression defined as  $\geq 6$  for *ESR1* and  $\geq 4.5$  for *PGR* on the normalized logarithmic scale presented from Nanostring.